Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
- PMID: 19348713
- DOI: 10.1007/s11910-009-0035-4
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
Abstract
Assessment via MRI is an integral part of the management of primary brain tumors. However, reliance on imaging to determine treatment response is not without its pitfalls. Necrosis is a known late effect of radiation treatment of the brain that can mimic tumor recurrence. It is now appreciated that pseudoprogression, a similar effect, can occur after combined chemoradiotherapy and can occur more quickly and dramatically than after radiation alone. Although several adjunct imaging modalities are under investigation, none is yet widely accepted as being able to distinguish between true progression and pseudoprogression. Conversely, at disease progression, antiangiogenic therapies are frequently used and can have a rapid positive effect on imaging. These changes, increasingly known as "pseudoresponses," can occur immediately after initiating treatment, making accurate assessment of true tumor response difficult. This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response.
Similar articles
-
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.Radiol Clin North Am. 2019 Nov;57(6):1199-1216. doi: 10.1016/j.rcl.2019.07.003. Epub 2019 Aug 16. Radiol Clin North Am. 2019. PMID: 31582045 Review.
-
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.Neuroimaging Clin N Am. 2021 Feb;31(1):103-120. doi: 10.1016/j.nic.2020.09.010. Neuroimaging Clin N Am. 2021. PMID: 33220823 Review.
-
Post-treatment imaging changes in primary brain tumors.Curr Oncol Rep. 2014;16(8):397. doi: 10.1007/s11912-014-0397-x. Curr Oncol Rep. 2014. PMID: 24997979 Review.
-
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.Lancet Oncol. 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. Lancet Oncol. 2008. PMID: 18452856 Review.
-
Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.Contrast Media Mol Imaging. 2018 Dec 2;2018:6828396. doi: 10.1155/2018/6828396. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 30627060 Free PMC article. Review.
Cited by
-
Quantitative Relaxometry Metrics for Brain Metastases Compared to Normal Tissues: A Pilot MR Fingerprinting Study.Cancers (Basel). 2022 Nov 15;14(22):5606. doi: 10.3390/cancers14225606. Cancers (Basel). 2022. PMID: 36428699 Free PMC article.
-
Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.J Neurooncol. 2010 Oct;100(1):17-29. doi: 10.1007/s11060-010-0139-3. Epub 2010 Feb 24. J Neurooncol. 2010. PMID: 20179990 Review.
-
New applications of nanotechnology for neuroimaging.AJNR Am J Neuroradiol. 2014 Jul;35(7):1246-53. doi: 10.3174/ajnr.A3543. Epub 2013 Mar 28. AJNR Am J Neuroradiol. 2014. PMID: 23538408 Free PMC article.
-
Circulating tumor cell is a common property of brain glioma and promotes the monitoring system.Oncotarget. 2016 Nov 1;7(44):71330-71340. doi: 10.18632/oncotarget.11114. Oncotarget. 2016. PMID: 27517490 Free PMC article.
-
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.J Clin Oncol. 2010 May 1;28(13):2293-9. doi: 10.1200/JCO.2009.25.3971. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368564 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical